Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MDM2 positive |
Therapy | YF438 |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MDM2 positive | triple-receptor negative breast cancer | sensitive | YF438 | Preclinical | Actionable | In a preclinical study, YF438 treatment inhibited H3 and H4 acetylation, promoted Mdm2 degradation, led to growth inhibition and increased apoptosis in triple-negative breast cancer cell lines in culture, and reduced tumor growth and metastasis, extended overall survival in an orthotopic autograft model (PMID: 33985974). | 33985974 |
PubMed Id | Reference Title | Details |
---|---|---|
(33985974) | Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer. | Full reference... |